umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Kriström, Berit
Alternative names
Publications (10 of 48) Show all publications
Ankarberg-Lindgren, C., Gawlik, A., Kriström, B., Mazzanti, L., Ruijgrok, E. J. & Sas, T. C. J. (2019). Estradiol matrix patches for pubertal induction: stability of cut pieces at different temperatures. Endocrine Connections, 8(4), 360-366
Open this publication in new window or tab >>Estradiol matrix patches for pubertal induction: stability of cut pieces at different temperatures
Show others...
2019 (English)In: Endocrine Connections, ISSN 2049-3614, E-ISSN 2049-3614, Vol. 8, no 4, p. 360-366Article in journal (Refereed) Published
Abstract [en]

Objective: Transdermal estradiol patches are primarily designed for adult women. No low-dose patches are licensed for pubertal induction in hypogonadal girls. Low doses can be achieved by cutting a matrix patch into smaller pieces. However, the manufacturers do not guarantee stability or utility of cut estradiol patches. The aim of the study was to assess 1-month stability of cut estradiol patches from four different manufacturers in the laboratory at room temperature (+21 degrees C) and at an elevated temperature (+35 degrees C).

Design and methods: Estraderm MX 50 mu g, Systen 50 mu g and Oesclim 25 mu g matrix patches were cut into eight pieces while Estradot 50 mu g small patches were cut in half. The cut patches were stored in their respective pouches at +21 degrees C or at +35 degrees C for up to 1 month. The estradiol drug was extracted from the patch by ethyl acetate n-hexane and determined by radioimmunoassay.

Results: Storage at +21 degrees C or +35 degrees C up to 1 month did not reduce the estradiol concentration in Estraderm MX, Systen and Oesclim patches. However, although the estradiol in Estradot patches was not affected by storage at +21 degrees C, at +35 degrees C, estradiol decreased by 57% (+/- 1%) in cut pieces.

Conclusions: Unused Estraderm MX, Systen and Oesclim patch pieces may be stored for at least 1 month at <=+35 degrees C. Where estradiol patches for children are not available, cut pieces of these or similar patches can be used for pubertal induction. The Estradot patch was too small to properly cut into low doses and not stable in elevated temperatures.

Place, publisher, year, edition, pages
Bioscientifica, 2019
Keywords
estrogen, hormone replacement therapy, patches, pubertal induction, stability
National Category
Endocrinology and Diabetes Pediatrics
Identifiers
urn:nbn:se:umu:diva-158741 (URN)10.1530/EC-19-0025 (DOI)000463769100007 ()30851161 (PubMedID)
Available from: 2019-05-20 Created: 2019-05-20 Last updated: 2019-05-20Bibliographically approved
Decker, R., Albertsson-Wikland, K., Kriström, B., Halldin, M., Gustafsson, J., Nilsson, N.-Ö. & Dahlgren, J. (2019). GH Dose Reduction Maintains Normal Prepubertal Height Velocity After Initial Catch-Up Growth in Short Children. Journal of Clinical Endocrinology and Metabolism, 104(3), 835-844
Open this publication in new window or tab >>GH Dose Reduction Maintains Normal Prepubertal Height Velocity After Initial Catch-Up Growth in Short Children
Show others...
2019 (English)In: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 104, no 3, p. 835-844Article in journal (Refereed) Published
Abstract [en]

Context: GH responsiveness guides GH dosing during the catch-up growth (CUG) period; however, little is known regarding GH dosing during the prepubertal maintenance treatment period.

Objective: To evaluate whether SD score (SDS) channel parallel growth with normal height velocity can be maintained after CUG by reducing the GH dose by 50% in children receiving doses individualized according to estimated GH responsiveness during the catch-up period.

Design and Settings: Prepubertal children (n = 98; 72 boys) receiving GH during CUG (GH deficient, n = 33; non–GH deficient, n = 65), were randomized after 2 to 3 years to either a 50% reduced individualized dose (GHRID; n = 27; 20 boys) or unchanged individualized dose (GHUID; n = 38; 27 boys). Another 33 children (25 boys) continued a standard weight-based dose [43 µg/kg/d (GHFIX)].

Main Outcome Measures: The primary endpoint was the proportion of children with ΔheightSDS within ±0.3 at 1 year after GH dose reduction compared with two control groups: GHUIDand GHFIX. The hypothesis was that heightSDS could be maintained within ±0.3 with a reduced individualized GH dose.

Results: For the intention-to-treat population at 1 year, 85% of the GHRIDgroup maintained ΔheightSDS within ±0.3 vs 41% in the GHUIDgroup (P = 0.0055) and 48% in the GHFIXgroup (P = 0.0047). The ΔIGF-ISDS in the GHRID group was −0.75 ± 1.0 at 3 months (P = 0.003) and −0.72 ± 1.2 at 1 year compared with the GHUID group (0.15 ± 1.2; P = 0.005) and GHFIX group (0.05 ± 1.0; P = 0.02).

Conclusions: Channel parallel growth (i.e., normal height velocity) and IGF-ISDS levels within ±2 were maintained after completed CUG using a 50% lower individualized dose than that used during the CUG period.

Place, publisher, year, edition, pages
Oxford University Press, 2019
National Category
Pediatrics Endocrinology and Diabetes
Identifiers
urn:nbn:se:umu:diva-158115 (URN)10.1210/jc.2018-01006 (DOI)000462737000034 ()30339244 (PubMedID)
Funder
Swedish Research Council, 522-2005-7238Swedish Research Council, 7509
Available from: 2019-04-12 Created: 2019-04-12 Last updated: 2019-04-12Bibliographically approved
Donaldson, M., Kriström, B., Ankarberg-Lindgren, C., Verlinde, S., van Alfen-van der Velden, J., Gawlik, A., . . . Zuckerman-Levin, N. (2019). Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy. Hormone Research in Paediatrics, 91(3), 153-163
Open this publication in new window or tab >>Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy
Show others...
2019 (English)In: Hormone Research in Paediatrics, ISSN 1663-2818, E-ISSN 1663-2826, Vol. 91, no 3, p. 153-163Article, review/survey (Refereed) Published
Abstract [en]

Background: Most girls with Turner syndrome (TS) require pubertal induction with estrogen, followed by long term replacement. However, no adequately powered prospective studies comparing transdermal with oral 17β-estradiol administration exist. This reflects the difficulty of securing funding to study a rare condition with relatively low morbidity/mortality when competing against conditions such as cancer and vascular disease. Protocol Consensus: The TS Working Group of the European Society for Paediatric Endocrinology (ESPE) has agreed to both a 3-year oral and a 3-year transdermal regimen for pubertal induction. Prerequisites include suitable 17β-estradiol tablets and matrix patches to allow the delivery of incremental doses based on body weight. Study Proposal: An international prospective cohort study with single centre analysis is proposed in which clinicians and families are invited to choose either of the agreed regimens, usually starting at 11 years. We hypothesise that pubertal induction with transdermal estradiol will result in better outcomes for some key parameters. The primary outcome measure chosen is height gain during the induction period. Analysis: Assessment of the demographics and drop-out rates of patients choosing either oral or transdermal preparations; and appropriate analysis of outcomes including pubertal height gain, final height, liver enzyme and lipid profile, adherence/acceptability, cardiovascular health, including systolic and diastolic blood pressure and aortic root diameter and bone health. Conclusion: The proposed model of prospective data collection according to internationally agreed protocols aims to break the current impasse in obtaining evidence-based management for TS and could be applied to other rare paediatric endocrine conditions.

Place, publisher, year, edition, pages
S. Karger, 2019
Keywords
Turner syndrome, Puberty, 17 beta-estradiol, Oral induction, Transdermal induction
National Category
Pediatrics
Identifiers
urn:nbn:se:umu:diva-161936 (URN)10.1159/000500050 (DOI)000476517300001 ()31167218 (PubMedID)2-s2.0-85067085208 (Scopus ID)
Available from: 2019-08-06 Created: 2019-08-06 Last updated: 2019-08-06Bibliographically approved
Kanumakala, S., Pfaffle, R., Hoybye, C., Kriström, B., Battelino, T., Zabransky, M. & Zouater, H. (2018). Latest Results from PATRO Children, A Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope (R) in Children Requiring Growth Hormone Treatment. Hormone Research in Paediatrics, 90, 124-124
Open this publication in new window or tab >>Latest Results from PATRO Children, A Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope (R) in Children Requiring Growth Hormone Treatment
Show others...
2018 (English)In: Hormone Research in Paediatrics, ISSN 1663-2818, E-ISSN 1663-2826, Vol. 90, p. 124-124Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
S. Karger, 2018
National Category
Pediatrics
Identifiers
urn:nbn:se:umu:diva-152923 (URN)000445204101002 ()
Note

Supplement: 1

Meeting Abstract: RFC15.6

Available from: 2018-10-30 Created: 2018-10-30 Last updated: 2019-04-01Bibliographically approved
Ankarberg-Lindgren, C., Gawlik, A., Kriström, B., Mazzanti, L. & Sas, T. C. J. (2018). Sustainability of Estradiol Drug Concentrations in Cut Matrix Patches; A Study of Different Brands with Potential Use for Pubertal Induction. Hormone Research in Paediatrics, 90, 553-553
Open this publication in new window or tab >>Sustainability of Estradiol Drug Concentrations in Cut Matrix Patches; A Study of Different Brands with Potential Use for Pubertal Induction
Show others...
2018 (English)In: Hormone Research in Paediatrics, ISSN 1663-2818, E-ISSN 1663-2826, Vol. 90, p. 553-553Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
S. Karger, 2018
National Category
Pediatrics
Identifiers
urn:nbn:se:umu:diva-152922 (URN)000445204104069 ()
Note

Supplement: 1

Meeting Abstract: P1-P239

Available from: 2018-10-30 Created: 2018-10-30 Last updated: 2019-04-01Bibliographically approved
Duchén, K., Lindberg, A., Kiplok, K. & Kriström, B. (2017). Using a spontaneous profile rather than stimulation test makes the KIGS idiopathic growth hormone deficiency model more accessible for clinicians. Acta Paediatrica, 106(9), 1481-1486
Open this publication in new window or tab >>Using a spontaneous profile rather than stimulation test makes the KIGS idiopathic growth hormone deficiency model more accessible for clinicians
2017 (English)In: Acta Paediatrica, ISSN 0803-5253, E-ISSN 1651-2227, Vol. 106, no 9, p. 1481-1486Article in journal (Refereed) Published
Abstract [en]

Aim: Children treated with a growth hormone (GH) for idiopathic growth hormone deficiency (IGHD) may be monitored with the first-year prediction model from the Pfizer International Growth Database (KIGS) using auxology, age, GH dose and the maximum GH concentration from a stimulation test (GH(max)stim). We tested the hypothesis that using a 12-hour spontaneous profile (GH(max)12h) would be as accurate. Methods: We studied 98 prepubertal Swedish children (78boys) aged2-12 years enrolled in KIGS. The first-year growth was predicted using the GH(max) from the GHprofile and a stimulation test, and both of these were compared separately with the observed growth response. Results: The increased height observed in the first year was 0.74 standard deviation scores (SDS), and the studentised residuals for the predicted and observed growth with GH(max)stim (-0.16 SDS) and GH(max)12h (-0.22) were similar. Individual predictions calculated with stimulated or spontaneous GH(max) showed a significant correlation (r = 0.80). Conclusion: We validated the KIGS IGHD prediction model and found that the stimulated GH(max) peak can be reliably replaced by the GH(max) 12h with similar accuracy. This makes the model more accessible for clinicians, who can then provide realistic expectations for the growth response during the first year of treatment.

Place, publisher, year, edition, pages
John Wiley & Sons, 2017
Keywords
Growth hormone treatment, Growth response, Idiopathic growth hormone deficiency, Prediction del, Short stature
National Category
Pediatrics
Identifiers
urn:nbn:se:umu:diva-139811 (URN)10.1111/apa.13932 (DOI)000409343900018 ()28543706 (PubMedID)
Available from: 2017-09-26 Created: 2017-09-26 Last updated: 2019-04-01Bibliographically approved
Lundberg, E., Andersson, B., Kriström, B., Rosberg, S. & Albertsson-Wikland, K. (2016). Are the GH Treatment Doses in Use within Secretion Rates of Healthy Children?. Paper presented at European Society for Paediatric Endocrinology (ESPE)55th Annual Meeting, Paris, September 10-12, 2016. Hormone Research in Paediatrics, 86, 378-378
Open this publication in new window or tab >>Are the GH Treatment Doses in Use within Secretion Rates of Healthy Children?
Show others...
2016 (English)In: Hormone Research in Paediatrics, ISSN 1663-2818, E-ISSN 1663-2826, Vol. 86, p. 378-378Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
S. Karger, 2016
National Category
Endocrinology and Diabetes Pediatrics
Identifiers
urn:nbn:se:umu:diva-129776 (URN)000384166801282 ()
Conference
European Society for Paediatric Endocrinology (ESPE)55th Annual Meeting, Paris, September 10-12, 2016
Note

Supplement: 1

Meeting Abstract: P1-P631

Available from: 2017-01-09 Created: 2017-01-09 Last updated: 2019-04-01Bibliographically approved
Albertsson-Wikland, K., Mårtensson, A., Sävendahl, L., Niklasson, A., Bang, P., Dahlgren, J., . . . Oden, A. (2016). Birth Characteristics Explain One Third of Expected Deaths in rhGH-treated Patients Diagnosed with IGHD, ISS & SGA. Paper presented at European Society for Paediatric Endocrinology (ESPE), 55th Annual Meeting, Paris, September 10-12, 2016. Hormone Research in Paediatrics, 86, 49-49
Open this publication in new window or tab >>Birth Characteristics Explain One Third of Expected Deaths in rhGH-treated Patients Diagnosed with IGHD, ISS & SGA
Show others...
2016 (English)In: Hormone Research in Paediatrics, ISSN 1663-2818, E-ISSN 1663-2826, Vol. 86, p. 49-49Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
S. Karger, 2016
National Category
Endocrinology and Diabetes Pediatrics
Identifiers
urn:nbn:se:umu:diva-129774 (URN)000384166800117 ()
Conference
European Society for Paediatric Endocrinology (ESPE), 55th Annual Meeting, Paris, September 10-12, 2016
Note

Supplement: 1

Meeting Abstract: FC8.6

Available from: 2017-01-09 Created: 2017-01-09 Last updated: 2019-04-01Bibliographically approved
Pfäffle, R., Kanumakala, S., Höybye, C., Kriström, B., Zabransky, M., Battelino, T. & Colle, M. (2016). Four-Year Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope (R) in Children Requiring Growth Hormone Treatment. Paper presented at European Society for Paediatric Endocrinology (ESPE), 55th Annual Meeting, Paris, September 10-12, 2016. Hormone Research in Paediatrics, 86, 379-379
Open this publication in new window or tab >>Four-Year Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope (R) in Children Requiring Growth Hormone Treatment
Show others...
2016 (English)In: Hormone Research in Paediatrics, ISSN 1663-2818, E-ISSN 1663-2826, Vol. 86, p. 379-379Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
S. Karger, 2016
National Category
Endocrinology and Diabetes Pediatrics
Identifiers
urn:nbn:se:umu:diva-129777 (URN)000384166801285 ()
Conference
European Society for Paediatric Endocrinology (ESPE), 55th Annual Meeting, Paris, September 10-12, 2016
Note

Supplement: 1

Meeting Abstract: P1-P634

Available from: 2017-01-09 Created: 2017-01-09 Last updated: 2019-04-01Bibliographically approved
Lundberg, E., Andersson, B., Kriström, B., Rosberg, S. & Albertsson-Wikland, K. (2016). GH-Pattern with High Trophs are Often Found after Daily sc rhGH-Injection in Children. Paper presented at European Society for Paediatric Endocrinology (ESPE)55th Annual Meeting, Paris, September 10-12, 2016. Hormone Research in Paediatrics, 86, 377-377
Open this publication in new window or tab >>GH-Pattern with High Trophs are Often Found after Daily sc rhGH-Injection in Children
Show others...
2016 (English)In: Hormone Research in Paediatrics, ISSN 1663-2818, E-ISSN 1663-2826, Vol. 86, p. 377-377Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
S. Karger, 2016
National Category
Endocrinology and Diabetes Pediatrics
Identifiers
urn:nbn:se:umu:diva-129775 (URN)000384166801281 ()
Conference
European Society for Paediatric Endocrinology (ESPE)55th Annual Meeting, Paris, September 10-12, 2016
Note

Supplement: 1

Meeting Abstract: P1-P630

Available from: 2017-01-09 Created: 2017-01-09 Last updated: 2019-04-01Bibliographically approved
Organisations

Search in DiVA

Show all publications